Marcellin, Patrick <br/><br/>
Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy.  [electronic resource] 

 -  Journal of hepatology  Jan 2015 
 - 41-7 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1600-0641 
<br/><br/><label>Standard No.: </label>10.1016/j.jhep.2014.08.021  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antiviral Agents--adverse effects<br/>DNA, Viral--analysis<br/>Drug Carriers<br/>Drug Therapy, Combination<br/>Female<br/>Global Health<br/>Hepatitis B e Antigens--immunology<br/>Hepatitis B virus--genetics<br/>Hepatitis B, Chronic--drug therapy<br/>Humans<br/>Incidence<br/>Interferon-alpha--adverse effects<br/>Male<br/>Peripheral Nervous System Diseases--diagnosis<br/>Polyethylene Glycols--adverse effects<br/>Recombinant Proteins--adverse effects<br/>Telbivudine<br/>Thymidine--adverse effects